Acute Intermittent Porphyria Market Size, Share, Growth Analysis, By Diagnosis, By Treatment, By End User, By Region

Description

Acute Intermittent Porphyria Market size was valued at USD 2.18 Billion in 2022 and is poised to grow from USD 2.32 Billion in 2023 to USD 3.72 Billion by 2031, at a CAGR of 6.10% during the forecast period (2024-2031).

The market for Acute Intermittent Porphyria (AIP) is experiencing significant developments driven by increased awareness, improved diagnostics, and evolving treatment options. AIP, a rare genetic disorder affecting heme synthesis, has gained prominence in the healthcare sector. Advances in diagnostics, including genetic testing, contribute to early and accurate detection of AIP cases. Pharmaceutical companies' focus on research and development for innovative therapies, coupled with enhanced patient education, supports the management of AIP symptoms. However, challenges such as underdiagnosis and limited treatment choices persist. A collaborative approach involving healthcare professionals, researchers, and pharmaceutical firms is essential for addressing the complexities of the AIP market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Acute Intermittent Porphyria market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Acute Intermittent Porphyria Market Segmental Analysis

The acute intermittent porphyria market is segmented into diagnosis, treatment, end user, and region. Based on diagnosis, the market is segmented into blood test, urine test, DNA test, and serum test. Based on treatment, the market is segmented into gonadotropin-releasing hormone analogues, and prophylactic hematin infusions. Based on end user, the market is segmented into hospitals, clinics, research centers, and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Drivers of the Acute Intermittent Porphyria Market

Increased attention and improved diagnostic capabilities have expedited the identification of AIP cases, enabling early intervention and effective management. Furthermore, advancements in treatment options, such as hematin infusions and emerging RNA interference (RNAi) therapies like givosiran, provide more effective strategies for managing acute attacks and long-term symptom control.

Restraints in the Acute Intermittent Porphyria Market

One of the primary challenges in the market is the substantial issue of underdiagnosis, primarily due to the rarity of AIP and the complexity of its symptoms, resulting in delayed or overlooked identification of affected individuals. Additionally, the market is constrained by limited treatment options, which focus more on symptom management rather than providing a cure.

Market Trends of the Acute Intermittent Porphyria Market

The progress in genetic testing technologies represents a significant trend, enabling more precise and timely diagnosis of AIP cases. The development of RNA interference (RNAi) therapies, as seen with medications such as givosiran, illustrates a transformative trend by offering a targeted approach to address the genetic factors underlying AIP.

Product Code: SQMIG35D2218

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Pricing Analysis
Start Up Analysis
Regulatory Landscape
Patent Analysis
Pipeline Analysis
Key Success Factors
Market Attractiveness Index
Degree of Competition
Top Investment Pockets
Ecosystem Mapping

Acute Intermittent Porphyria Market by Diagnosis

Market Overview
Blood Test
Urine Test
DNA Test
Serum Test

Acute Intermittent Porphyria Market by Treatment

Market Overview
Gonadotropin-Releasing Hormone Analogues
Prophylactic Hematin Infusions

Acute Intermittent Porphyria Market by End User

Market Overview
Hospitals
Clinics
Research Centers
Others

Acute Intermittent Porphyria Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Alnylam Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recordati Rare Diseases
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lubeck Pharmaceuticals GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharming Group N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi Genzyme
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AmerisourceBergen Specialty Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cardinal Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
McKesson Specialty Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alliance Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LabCorp
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mayo Clinic Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Porphyria Foundation International
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
National Organization for Rare Disorders
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
European Porphyria Network
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Porphyrias Australia
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

Acute Intermittent Porphyria Market Size, Share, Growth Analysis, By Diagnosis, By Treatment, By End User, By Region - Industry Forecast 2024-2031